Here you will find the Publications from 2010 onwards.
Risk assessment of parabens in a transcriptomics-based in vitro test. Chem Biol Interact 384: 110699 (2023)
Increased sinusoidal export of drug glucuronides is a compensative mechanism in liver cirrhosis of mice. Front Pharmacol 14: 1279357 (2023) (14 pp)
Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth. J Exp Clin Cancer Res 42 (1): 25 (2023) (18 pp)
Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis. Nat Commun 14 (1): 3304 (2023) (17 pp)
Transcriptomic cross-species analysis of chronic liver disease reveals consistent regulation between humans and mice. Hepatol Commun 6: 161-177 (2022)
The hepatocyte export carrier inhibition assay improves the separation of hepatotoxic from non-hepatotoxic compounds. Chem Biol Interact 351: 109728 (2022) (16 pp)
Identification of an FXR-modulated liver-intestine hybrid state in iPSC-derived hepatocyte-like cells. J Hepatol 77: 1386-1398 (2022)
Classification of developmental toxicants in a human iPSC transcriptomics-based test. Chem Res Toxicol 35: 760–773 (2022)
In vitro/in silico prediction of drug induced steatosis in relation to oral doses and blood concentrations by the Nile Red assay. Toxicol Lett 368: 33-46 (2022)